ITM to Present at Raymond James Private Biotech Symposium
18 févr. 2025 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, February 18, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Raymond James Private Biotech...
ITM to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
07 févr. 2025 08h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, February 7, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in Oppenheimer’s 35th Annual Healthcare...
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
29 janv. 2025 17h30 HE
|
Silexion Therapeutics Corp
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
$995.7 Million Spatial Genomics & Transcriptomics Market Global Forecast to 2029
29 janv. 2025 07h54 HE
|
Research and Markets
Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Spatial Genomics & Transcriptomics Market by Product (Instruments, Consumables, Services), Technique (Transcriptomics (IHC, ISH), Genomics (LCM),...
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
28 janv. 2025 08h29 HE
|
Silexion Therapeutics Corp
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...
ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
28 janv. 2025 05h00 HE
|
ITM Isotope Technologies Munich SE
Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimusITM plans...
Delta-like Ligand 3 (DLL3) Targeted Therapies Market Research 2025: 1 Drug, Imdelltra (Tarlatamab) Available / 10 Drugs by Company, Indication and Phase / Approved Drug Dosage, Sales & Pricing Insight
23 janv. 2025 07h51 HE
|
Research and Markets
Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's...
Precision Medicine Collaboration and Licensing Deals 2019-2024
16 janv. 2025 06h03 HE
|
Research and Markets
Dublin, Jan. 16, 2025 (GLOBE NEWSWIRE) -- The "Precision Medicine Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. This report contains a...
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
15 janv. 2025 20h00 HE
|
Silexion Therapeutics Corp
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
15 janv. 2025 16h01 HE
|
Silexion Therapeutics Corp
Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...